Industry Focus

Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.

Direct download: 20170712_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT

1